A comparison of the analytical performance of five commercially available assays for neutrophil gelatinase-associated lipocalin using urine

Annals of Clinical Biochemistry

Volumn 50, Issue 3, 2013, Pages 236-244

  Kift, Rebecca L ^a   Messenger, Michael P ^b   Wind, Tobias C ^b   Hepburn, Sophie ^b   Wilson, Michelle ^b   Thompson, Douglas ^a,b   Smith, Matthew Welberry ^b   Sturgeon, Catharine ^c   Lewington, Andrew J ^b   Selby, Peter J ^b   Banks, Rosamonde E ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ACUTE KIDNEY FAILURE; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIMIT OF QUANTITATION; PRIORITY JOURNAL; PROBLEM IDENTIFICATION; STANDARDIZATION; URINALYSIS;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOCALINS; PROTO-ONCOGENE PROTEINS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY;

EID: 84879432026     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2012.012117     Document Type: Article

References (36)

1. Murugan R, Kellum JA. Acute kidney injury: what's the prognosis? Nat Rev Nephrol 2011;7:209-17
2. Kjeldsen L, Johnsen AH, Sengelov H, Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem 1993;268:10425-32
3. Paragas N, Qiu A, Zhang Q, et al. The Ngal reporter mouse detects the response of the kidney to injury in real time. Nat Med 2011;17:216-22
4. Mishra J, Ma Q, Prada A, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003;14:2534-43
5. Cai L, Rubin J, Han W, Venge P, Xu S. The origin of multiple molecular forms in urine of HNL/NGAL. Clin J Am Soc Nephrol 2010;5:2229-35
6. Schmidt-Ott KM, Mori K, Li JY, et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2007;18:407-13
7. Haase M, Bellomo R, Devarajan P, et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009;54:1012-24
8. Parikh CR, Lu JC, Coca SG, Devarajan P. Tubular proteinuria in acute kidney injury: a critical evaluation of current status and future promise. Ann Clin Biochem 2010;47:301-12
9. Ronco C, Grammaticopoulos S, Rosner M, et al. Oliguria, creatinine and other biomarkers of acute kidney injury. Contrib Nephrol 2010;164:118-27
10. Siew ED, Ware LB, Ikizler TA. Biological markers of acute kidney injury. J Am Soc Nephrol 2011;22:810-20
11. Devarajan P. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Nephrology 2010;15:419-28
12. Nickolas TL, Schmidt-Ott KM, Canetta P, et al. Diagnostic and prognostic stratification in the emergency department using urinary biomarkers of nephron damage a multicenter prospective cohort study. J Am Coll Cardiol 2012;59:246-55
13. Hollmen ME, Kyllonen LE, Inkinen KA, et al. Deceased donor neutrophil gelatinase-associated lipocalin and delayed graft function after kidney transplantation: a prospective study. Crit Care 2011;15:R121
14. Hollmen ME, Kyllonen LE, Inkinen KA, Lalla MLT, Salmela KT. Urine neutrophil gelatinase-associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney Int 2011;79:89-98
15. Sturgeon C, Hill R, Hortin GL, Thompson D. Taking a new biomarker into routine use - a perspective from the routine clinical biochemistry laboratory. Proteomics Clin Appl 2010;4:892-903
16. Grenier FC, Ali S, Syed H, et al. Evaluation of the ARCHITECT urine NGAL assay: assay performance, specimen handling requirements and biological variability. Clin Biochem 2010;43:615-20
17. Lippi G, Aloe R, Storelli A, Cervellin G, Trenti T. Evaluation of NGAL TestTM, a fully-automated neutrophil gelatinase-associated lipocalin (NGAL) immunoassay on Beckman Coulter AU 5822. Clin Chem Lab Med 2012;50:1581-4
18. Pedersen KR, Ravn HB, Hjortdal VE, Norregaard R, Povlsen JV. Neutrophil gelatinase-associated lipocalin (NGAL): validation of commercially available ELISA. Scand J Clin Lab Invest 2010;70:374-82
19. Cavalier E, Bekaert AC, Carlisi A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) determined in urine with the Abbott Architect or in plasma with the Biosite Triage? The laboratory's point of view. Clin Chem Lab Med 2011;49:339-41
20. Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31
21. Food and Drug Administration. Draft Guidance for Industry: bioanalytical method validation US Department of Health and Human Services, FDA, Center for Drug Evaluation and Research (CDER), Rockville, MD
22. McEnroe RJ, Burrit MF, Powers DM, Rheinheimer DW, Wallace BH. Interference testing in clinical chemistry: approved guideline second edition (EP7-A2). 2005;25
23. Krouwer JS, Tholen DW, Garber CC, et al. Method comparison and bias estimation using patient samples; approved guideline - second edition (EP9-A2). 2002;22
24. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006;23:312-28
25. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;327:307-10
26. Furness P, Zimmern R, Wright C, Adams M. The evaluation of diagnostic laboratory tests and complex biomarkers: Summary of a Diagnostic Summit 2008 See www.phgfoundation.org/file/3998/ (last accessed 9 November 2012)
27. Poste G. Bring on the biomarkers. Nature 2011;469:156-7
28. Phillips KA, Van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov 2006;5:463-9
29. Haase M, Devarajan P, Haase-Fielitz A, et al. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol 2011;57:1752-61
30. Zhao C, Ozaeta P, Fishpaugh J, et al. Structural characterization of glycoprotein NGAL, an early predictive biomarker for acute kidney injury. Carbohydr Res 2010;345:2252-61
31. Cai L, Borowiec J, Xu S, Han W, Venge P. Assays of urine levels of HNL/ NGAL in patients undergoing cardiac surgery and the impact of antibody configuration on their clinical performances. Clin Chim Acta 2009;403:121-5
32. Kjeldsen L, Bainton DF, Sengelov H, Borregaard N. Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils. Blood 1994;83:799-807
33. Kjeldsen L, Koch C, Arnljots K, Borregaard N. Characterization of two ELISAs for NGAL, a newly described lipocalin in human neutrophils. J Immunol Methods 1996;198:155-64
34. Thrailkill KM, Moreau CS, Cockrell GE, et al. Disease and gender-specific dysregulation of NGAL and MMP-9 in type 1 diabetes mellitus. Endocrine 2010;37:336-43
35. Cullen MR, Murray PT, Fitzgibbon MC. Establishment of a reference interval for urinary neutrophil gelatinase-associated lipocalin. Ann Clin Biochem 2012;49:190-3
36. Tomonaga Y, Szucs T, Ambuhl P, et al. Insights on urinary NGAL obtained in a primary care setting. Clin Chim Acta 2012;413:733-9